Dublin-based pharmaceutical giant Shire offloads oncology business for $2.4bn

Dublin-based pharmaceutical giant Shire offloads oncology business for $2.4bn

Pharmaceutical giant Shire has agreed to sell its oncology business to French firm Servier for $2.4bn ahead of a potential takeover offer by Japan's Takeda.

The drug-maker's board has given the green light to the deal, which does not require shareholder approval and is now expected to close in the second or third quarter of 2018.

The firm, which has its headquarters in Dublin, started looking at offloading the oncology business in December, and said the process considered "multiple potential strategic buyers" across Europe, Japan and the US.

Shire said it was considering returning proceeds of the sale to investors through a share buyback programme after the current offer period - during which Takeda could launch a formal bid - expires.

Shire chief executive Flemming Ornskov said: "This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio.

"While the oncology business has delivered high growth and profitability, we have concluded that it is not core to Shire's longer-term strategy.

"We will continue to evaluate our portfolio for opportunities to unlock further value and sharpen our focus on rare disease leadership with selective disposals of non-strategic assets.

"We are confident that Servier will continue to invest in this business and our colleagues who are expected to transfer as part of the transaction in order to meet the needs of cancer patients globally."

Shire shares rose as much as 1.8% on the back of the news.

The company's stock price surged last month after Osaka-based Takeda said it was considering making a takeover approach for the £32.8 billion valued firm.

Some experts have questioned how any potential deal will be funded, given that Takeda is worth billions less than its takeover target.

Reports over the weekend suggested that Takeda had approached lenders about providing the cash, and that its chief executive was on its way to the US to meet with top investors ahead of making a potential offer.

Takeda, which was founded in 1781 and employs 30,000 people, has a strong presence in emerging markets and operates in more than 70 countries.

It said last month that a potential transaction with Shire presented an opportunity to create a "truly global, value-based Japanese biopharmaceutical leader", strengthening its core oncology, gastrointestinal and neuroscience offerings.

In addition, a tie-up would help realise the Japanese company's R&D strategy, drive financial value and allow it to exploit further opportunities in the US.

If a deal were to be struck, it would see the hunter become the hunted after Shire itself went on the acquisition trail only two years ago when it bought Baxalta for $32bn.

Last year, Shire's revenues doubled following the takeover to $3.57bn, the bulk of which came from the Baxalta business.

When stripped of legacy Baxalta sales, revenues rose only 11% to $1.8bn.

Commenting on its purchase of Shire's oncology business, Servier Group president Olivier Laureau said: "This acquisition allows us to establish a direct commercial presence in the United States, the world's leading pharmaceuticals market, and to strengthen our portfolio of marketed products in the territories where Servier is already present.

"Our goal is to bring these treatments to greater numbers of cancer patients around the world. We thoroughly look forward to welcoming Shire's oncology teams who will join Servier after the closing."

-Press Association

More on this topic

Expansion costs hit profits at three time Oscar-nominated Cartoon Saloon animation studiosExpansion costs hit profits at three time Oscar-nominated Cartoon Saloon animation studios

Novartis firm posted sales of €112mNovartis firm posted sales of €112m

Two key appointments at e-commerce groupTwo key appointments at e-commerce group

Businesses without online presence considered 'outdated' by two-thirds of Irish consumersBusinesses without online presence considered 'outdated' by two-thirds of Irish consumers

More in this Section

Corporate tax windfalls remain a puzzleCorporate tax windfalls remain a puzzle

Expansion costs hit profits at three time Oscar-nominated Cartoon Saloon animation studiosExpansion costs hit profits at three time Oscar-nominated Cartoon Saloon animation studios

Tariff and quota-free trade between Ireland and Britain must remain – VaradkarTariff and quota-free trade between Ireland and Britain must remain – Varadkar

BT shares plunge after Labour’s free broadband promiseBT shares plunge after Labour’s free broadband promise


Lifestyle

Kate Tempest’s Vicar Street show began with the mother of all selfie moments. The 33 year-old poet and rapper disapproves of mid-concert photography and instructed the audience to get their snap-happy impulses out of the way at the outset. What was to follow would, she promised, be intense. We should give ourselves to the here and now and leave our phones in our pockets.Kate Tempest dives deep and dark in Dublin gig

Des O'Sullivan examines the lots up for auction in Bray.A Week in Antiques: Dirty tricks and past political campaigns

Following South Africa’s deserved Rugby World Cup victory I felt it was about time that I featured some of their wines.Wine with Leslie Williams

All your food news.The Menu: Food news with Joe McNamee

More From The Irish Examiner